Grifols (GRFS) P/E (2011 - 2026)
Grifols (GRFS) P/E from Jun 2, 2011 to Jul 21, 2026. The TTM Grifols (GRFS) P/E is 10.87. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Grifols (GRFS)
| Year | P/E | Change |
|---|---|---|
| 2026 | 10.87 | -20.71% |
| 2025 | 13.71 | -55.15% |
| 2024 | 30.56 | -55.62% |
| 2023 | 68.86 | -40.86% |
| 2022 | 116.44 | +602.65% |
| 2021 | 16.57 | +9.78% |
| 2020 | 15.10 | -33.30% |
| 2019 | 22.63 | +27.17% |
| 2018 | 17.80 | -27.87% |
| 2017 | 24.67 | +33.62% |
| 2016 | 18.47 | -3.53% |
| 2015 | 19.14 | -0.40% |
| 2014 | 19.22 | -27.77% |
| 2013 | 26.61 | +0.94% |
| 2012 | 26.36 | -13.13% |
| 2011 | 30.34 | N/A |
Comparison Grifols (GRFS) P/E with competitors
Grifols (GRFS) P/E is 10.87.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| PFE | Pfizer Inc | 11.65 | +7.25% |
| NVO | Novo Nordisk | 11.79 | +8.51% |
| GSK | GSK Plc | 12.10 | +11.39% |
| SNY | Sanofi | 12.12 | +11.57% |
| BMY | Bristol-Myers Squibb Company | 13.82 | +27.17% |
| OGN | Organon & Company | 14.33 | +31.84% |
| BIIB | Biogen Inc | 17.41 | +60.17% |
| GILD | Gilead Sciences Inc | 17.75 | +63.30% |
| NVS | Novartis AG | 21.60 | +98.75% |
| JNJ | Johnson & Johnson | 22.09 | +103.26% |
| AMGN | AMGEN Inc | 24.75 | +127.77% |
| MRK | Merck & Co Inc | 26.93 | +147.80% |
| AZN | Astrazeneca plc | 28.44 | +161.75% |
| LLY | Lilly(Eli) & Company | 48.44 | +345.80% |
| ABBV | Abbvie Inc | 139.08 | +1179.89% |